← All trials
NCT06427395
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 16, 2024
- Primary completion
- Apr 18, 2027
- Completion date
- Jul 18, 2027
- First posted
- May 23, 2024
- Last posted
- Sep 5, 2024
- Enrollment
- 150
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Zydus Discovery DMCCLead sponsor
- Zydus Discovery DMCCOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.